Trends in Mortality Rates for Gastrointestinal Cancers in Fars Province, Iran (2005–2015)
- 15 Downloads
In Iran, cancers are the third leading cause of death, and gastrointestinal cancers are the primary cause of mortality among all the cancers. This study aimed to determine the trend of crude and age-standardized mortality rates (ASMR) for different types of gastrointestinal cancers over an 11-year period in Fars province (Iran).
In this study, all the mortality data for gastrointestinal cancers were derived from the Electronic Death Registration System (EDRS) between 2005 and 2015. Subsequently, we calculated the crude and age-standardized mortality rates (ASMR) and their trends for different types of gastrointestinal cancers based on age groups and gender over the study period.
A total of 6547 deaths from gastrointestinal cancers were identified, with an average age of 66.0 ± 16.4 years. The crude and age-standardized mortality rates for gastrointestinal cancers were respectively 10.9 and 15.0 per 100,000 population in 2005 which significantly increased to 17.4 and 19.4 per 100,000 population in 2015 (P < 0.001). The ASMR for colon, pancreatic, and oral cancers showed an increasing trend; for small intestine cancers, a decreasing trend; and for esophageal, gastric, rectal, and hepatobiliary cancers displayed an almost constant trend.
Our study shows a higher ASMR and an increasing trend of gastrointestinal cancers in Fars province. Prevention and early diagnosis programs with screening techniques should be implemented to control the mortality rate of gastrointestinal cancers in the future.
KeywordsGastrointestinal cancer Age-standardized mortality rate Trend Iran
This study was financially approved by Shiraz University of Medical Sciences, Shiraz, Iran (Grant number 96-01-109-14806).
Compliance with Ethical Standards
This study was conducted in compliance with the provisions of the Helsinki Declaration. The protocol was approved by the ethics committee of Shiraz University of Medical Sciences (No. IR.SUMS.REC. 1396.S619).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 7.Moradzadeh R, Golmohammadi P, Ghaitasi B, Nadrian H, Najafi A. Incidence of esophageal Cancer in Iran, a population-based study: 2001-2015. J Gastrointest Cancer. 2018. https://doi.org/10.1007/s12029-018-0114-3.
- 8.Reshadat S, Saeidi S, Zangeneh A, Ziapour A, Saeidi F, Choobtashani M. A comparative study of spatial distribution of gastrointestinal cancers in poverty and affluent strata (Kermanshah Metropolis, Iran). J Gastrointest Cancer. 2018. https://doi.org/10.1007/s12029-018-0163-7.
- 9.Salimzadeh H, Delavari F, Sauvaget C, Rezaee N, Delavari A, Kompani F, et al. Annual trends of gastrointestinal cancers mortality in Iran during 1990-2015; NASBOD study. Arch Iran Med. 2018;21(2):46–55.Google Scholar
- 10.Bray F, Soerjomataram I (2015) The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. In: Gelband H, Jha P, Sankaranarayanan R, Horton S (eds) Cancer: disease control priorities, third edition (volume 3). The International Bank for Reconstruction and Development / the World Bank (c) 2015 International Bank for Reconstruction and Development / the World Bank., Washington (DC). https://doi.org/10.1596/978-1-4648-0349-9_ch2.
- 16.Noroozian M. The elderly population in Iran: an ever growing concern in the health system. Iran J Psychiatry Behav Sci. 2012;6(2):1–6.Google Scholar
- 17.Pourhoseingholi MA, Fazeli Z, Ashtari S, Bavand-Pour FSF. Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S52–7.Google Scholar
- 19.Saadat S, Yousefifard M, Asady H, Moghadas Jafari A, Fayaz M, Hosseini M. The most important causes of death in Iranian population; a retrospective cohort study. Emergency (Tehran, Iran). 2015;3(1):16–21.Google Scholar
- 21.Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Annals of oncology: official journal of the European society for. Med Oncol. 2018;29(4):1016–22. https://doi.org/10.1093/annonc/mdy033.Google Scholar
- 22.Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpour A, Zali MR. Prognostic factors in gastric cancer using log-normal censored regression model. Indian J Med Res. 2009;129(3):262–7.Google Scholar
- 23.Pourhoseingholi MA, Baghestani A, Abadi A, Hajizadeh N. Iranian regional cancer incidence is misclassified in neighborhood's provinces. Gastroenterol Hepatol Bed Bench. 2016;9(2):75–7.Google Scholar
- 26.González-Santiago O, Yeverino-Gutiérrez ML, Del Rosario González-González M, Corral-Symes R, Morales-San-Claudio PC. Mortality assessment of patients with pancreatic cancer in Mexico, 2000-2014. Ecancermedicalscience. 2017;11:788–8. https://doi.org/10.3332/ecancer.2017.788.
- 27.Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VEPP, van Heijningen EB, Aragonés N, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol. 2014;109(3):336–44. https://doi.org/10.1038/ajg.2013.420.CrossRefGoogle Scholar
- 28.Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20 (11):2362–2368. doi: https://doi.org/10.1158/1055-9965.epi-11-0643.
- 29.Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Hepatis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. World J Gastroenterol. 2006;12(43):7025–8. https://doi.org/10.3748/wjg.v12.i43.7025.CrossRefGoogle Scholar
- 30.Joukar F, Mansour-Ghanaei F, Naghipour MR, Hassanipour S. Knowledge, distribution and risk factors of hepatitis B and C infection in high-risk groups in Guilan province, Iran. Hepat Mon. 2018;18(8). https://doi.org/10.5812/hepatmon.65870.
- 32.Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of National Responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI): a systematic review and meta-analysis study. Hepat Mon. 2015;15(5):e23618–8. https://doi.org/10.5812/hepatmon.15(04)2015.23618.